Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Department of Radiology, Radboud University Medical Center, Nijmegen, the Netherlands.
JNCI Cancer Spectr. 2021 Mar 21;5(3). doi: 10.1093/jncics/pkab026. eCollection 2021 Jun.
After resection of colorectal cancer liver metastases (CRLM), 2 main histopathological growth patterns can be observed: a desmoplastic and a nondesmoplastic subtype. The desmoplastic subtype has been associated with superior survival. These findings require external validation.
An international multicenter retrospective cohort study was conducted in patients treated surgically for CRLM at 3 tertiary hospitals in the United States and the Netherlands. Determination of histopathological growth patterns was performed on hematoxylin and eosin-stained sections of resected CRLM according to international guidelines. Patients displaying a desmoplastic histopathological phenotype (only desmoplastic growth observed) were compared with patients with a nondesmoplastic phenotype (any nondesmoplastic growth observed). Cutoff analyses on the extent of nondesmoplastic growth were performed. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier and multivariable Cox analysis. All statistical tests were 2-sided.
In total 780 patients were eligible. A desmoplastic phenotype was observed in 19.1% and was associated with microsatellite instability (14.6% vs 3.6%, = .01). Desmoplastic patients had superior 5-year OS (73.4%, 95% confidence interval [CI] = 64.1% to 84.0% vs 44.2%, 95% CI = 38.9% to 50.2%, < .001) and DFS (32.0%, 95% CI = 22.9% to 44.7% vs 14.7%, 95% CI = 11.7% to 18.6%, < .001) compared with their nondesmoplastic counterparts. A desmoplastic phenotype was associated with an adjusted hazard ratio for death of 0.36 (95% CI = 0.23 to 0.58) and 0.50 (95% CI = 0.37 to 0.66) for cancer recurrence. Prognosis was independent of and status. The cutoff analyses found no prognostic relationship between either OS or DFS and the extent of nondesmoplastic growth observed (all > .1).
This external validation study confirms the remarkably good prognosis after surgery for CRLM in patients with a desmoplastic phenotype. The extent of nondesmoplastic growth does not affect prognosis.
结直肠癌肝转移(CRLM)切除后,可观察到 2 种主要的组织病理学生长模式:纤维组织增生型和非纤维组织增生型。纤维组织增生型与更好的生存相关。这些发现需要外部验证。
这项在美国和荷兰的 3 家三级医院进行的国际多中心回顾性队列研究,对接受 CRLM 手术治疗的患者进行了研究。根据国际指南,对切除的 CRLM 的苏木精和伊红染色切片进行组织病理学生长模式的确定。表现出纤维组织增生型组织病理学表型(仅观察到纤维组织增生)的患者与表现出非纤维组织增生型表型(观察到任何非纤维组织增生)的患者进行比较。对非纤维组织增生的程度进行了截断分析。使用 Kaplan-Meier 和多变量 Cox 分析估计总生存(OS)和无病生存(DFS)。所有统计检验均为双侧。
共纳入 780 例患者。19.1%的患者表现出纤维组织增生型,与微卫星不稳定性(14.6%比 3.6%, = .01)相关。纤维组织增生型患者的 5 年 OS(73.4%,95%置信区间[CI] = 64.1%至 84.0%比 44.2%,95% CI = 38.9%至 50.2%, < .001)和 DFS(32.0%,95% CI = 22.9%至 44.7%比 14.7%,95% CI = 11.7%至 18.6%, < .001)均优于非纤维组织增生型患者。与非纤维组织增生型患者相比,纤维组织增生型患者的死亡调整风险比为 0.36(95% CI = 0.23 至 0.58)和 0.50(95% CI = 0.37 至 0.66)。预后与 KRAS 和 BRAF 状态无关。截断分析发现,无论是 OS 还是 DFS,与观察到的非纤维组织增生的程度之间均无预后关系(均 > .1)。
这项外部验证研究证实,在纤维组织增生型患者中,结直肠癌肝转移切除后的预后非常好。非纤维组织增生的程度并不影响预后。